Merck & Co., Inc. disclosed its financial results for the first quarter of 2023, showcasing a decline in sales and net income compared to the prior year. This resulted in decreased earnings per share. The company also made significant acquisitions, such as Prometheus Biosciences, Inc. and Imago BioSciences, Inc., and entered into partnerships like the one with AstraZeneca PLC for oncology treatments. The detailed financial statement covers adjustments and provides insights into the company's cash flows, investments, assets, liabilities, and equity. It also explains the company's financial position and operations. Additionally, the text delves into various aspects of the company's financial assets and liabilities, including investments in debt and equity securities, fair value measurements, unrealized gains and losses, and contingent considerations related to business combinations. It also covers topics such as loans payable, long-term debt, credit risk concentrations, inventories, and contingencies like legal proceedings and product liability claims.
The text provided includes detailed information on Merck's recent business developments, financial performance, and operational activities. It outlines major events such as the acquisition of Prometheus Biosciences, agreements with Kelun-Biotech, and the acquisition of Imago BioSciences. It also discusses Merck's sales performance, supply chain disruptions, pricing pressures in the healthcare sector, and an overview of the financial results for the first quarter of 2023. Additionally, it delves into Merck's product developments, with a focus on pharmaceuticals, vaccines, and the animal health segment. The text also highlights Merck's research and development pipeline, liquidity, capital resources, critical accounting estimates, and any recently issued accounting standards.
There have been no significant changes in market risk exposures since the Company's 2022 Form 10-K filing on February 24, 2023.
The text provided discusses the evaluation of disclosure controls and procedures over financial reporting by the Company's management, concluding that they are effective as of a specific date. It also highlights cautionary factors for future results, mentioning forward-looking statements and the potential impacts of risks and uncertainties. The Company emphasizes that actual results may differ from these forward-looking statements due to various factors outlined in their filings with the Securities and Exchange Commission. The text advises readers to consider all risk factors and bear in mind that it is impossible to predict or identify all potential risks or uncertainties.
The text provided is referencing legal proceedings and states that further information can be found in Note 8 of the Financial Statements in Part I.
I am ready to assist. Please provide the text you would like me to summarize.
During the three months ended March 31, 2023, the issuer purchased a total of 1,395,737 shares of equity securities at an average price of $107. These purchases were part of a plan approved by the Board of Directors in October 2018 to buy up to $10 billion of Merck's common stock for its treasury. The approximate dollar value of shares that may yet be purchased under the plan was $4,898 million as of March 31, 2023.
I'm ready to help you summarize the text. Please go ahead and provide the text you'd like me to summarize.
I'm ready to summarize the text for you. Please provide the text you would like me to summarize.
I am ready to receive the text parts for summarization. Please go ahead and provide the text.
The text provides a list of exhibits related to Merck & Co., Inc., including its restated Certificate of Incorporation and By-Laws, certifications of the Chief Executive Officer and Chief Financial Officer, and various XBRL documents. It concludes with signatures from company executives on May 5, 2023, including the Executive Vice President and General Counsel, Jennifer Zachary, and the Senior Vice President Finance - Global Controller, Rita A. Karachun.
